Desipramine treatment in panic disorder
Apart from imipramine (IMI), the efficacy of tricyclic antidepressants in panic disorder (PD) has received surprisingly little investigation. The authors report on a 6 week open trial of desipramine (DMI) preceded by a 10 day placebo lead-in, in 15 patients with PD. By week 6, 80% of the patients we...
Gespeichert in:
| Veröffentlicht in: | Journal of affective disorders 1991-04, Vol.21 (4), p.239-244 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 244 |
|---|---|
| container_issue | 4 |
| container_start_page | 239 |
| container_title | Journal of affective disorders |
| container_volume | 21 |
| creator | Kalus, Oren Asnis, Gregory M. Rubinson, Eileen Kahn, Rene Harkavy Friedman, Jill M. Iqbal, Naveed Grosz, Dan van Praag, Herman Cahn, Wiepke |
| description | Apart from imipramine (IMI), the efficacy of tricyclic antidepressants in panic disorder (PD) has received surprisingly little investigation. The authors report on a 6 week open trial of desipramine (DMI) preceded by a 10 day placebo lead-in, in 15 patients with PD. By week 6, 80% of the patients were globally rated as much or very much improved on a mean dose of 198 mg. Much of the improvement resulted from a reduction in non-panic attack symptomatology (i.e., psychic, somatic and phobic anxiety). longer duration of illness, male gender and residual psychic anxiety were associated with poorer response in a subgroup of patients. DMI caused minimal intolerable side effects, suggesting possible compliance advantages in comparison to IMI. Beyond supporting the efficacy of DMI in PD, the results of the study point to a significant medication responsive non-panic illness component and caution against over-relying on panic attacks in assessing both illness severity and treatment response. |
| doi_str_mv | 10.1016/0165-0327(91)90003-B |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80662782</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>016503279190003B</els_id><sourcerecordid>80662782</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-d5869a54d826471b7eaee14cf802de405ad9b658649a64922aaa479028ff63313</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMotVb_gcJsfC1Gk0wek41g6xMKbnQd0uQOROZlMhX896ZO0Z2Lw12c717uOQgdE3xFMBHXSTzHBZUXilwqjHGRz3fQlHBZ5JQTuYumv8g-OojxPTFCSTxBE1JSJRmfovM7iL4PpvEtZEMAMzTQDplvs9603mbOxy44CIdorzJ1hKPtnKG3h_vXxVO-fHl8Xtwuc1uUcsgdL4UynLmSCibJSoIBIMxWJaYOGObGqZVIEFMmiVJjDJMK07KqRFGQYobOxrt96D7WEAfd-Gihrk0L3TrqEgtBZUkTyEbQhi7GAJXug29M-NIE600_ehNeb8JrRfRPP3qe1k6299erBtzf0lhI8k-3vonW1FUwrfXxD1NCEsJZ4m5GDlIZnx6CjtZDa8H5AHbQrvP_P_INdHd_Ng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80662782</pqid></control><display><type>article</type><title>Desipramine treatment in panic disorder</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Kalus, Oren ; Asnis, Gregory M. ; Rubinson, Eileen ; Kahn, Rene ; Harkavy Friedman, Jill M. ; Iqbal, Naveed ; Grosz, Dan ; van Praag, Herman ; Cahn, Wiepke</creator><creatorcontrib>Kalus, Oren ; Asnis, Gregory M. ; Rubinson, Eileen ; Kahn, Rene ; Harkavy Friedman, Jill M. ; Iqbal, Naveed ; Grosz, Dan ; van Praag, Herman ; Cahn, Wiepke</creatorcontrib><description>Apart from imipramine (IMI), the efficacy of tricyclic antidepressants in panic disorder (PD) has received surprisingly little investigation. The authors report on a 6 week open trial of desipramine (DMI) preceded by a 10 day placebo lead-in, in 15 patients with PD. By week 6, 80% of the patients were globally rated as much or very much improved on a mean dose of 198 mg. Much of the improvement resulted from a reduction in non-panic attack symptomatology (i.e., psychic, somatic and phobic anxiety). longer duration of illness, male gender and residual psychic anxiety were associated with poorer response in a subgroup of patients. DMI caused minimal intolerable side effects, suggesting possible compliance advantages in comparison to IMI. Beyond supporting the efficacy of DMI in PD, the results of the study point to a significant medication responsive non-panic illness component and caution against over-relying on panic attacks in assessing both illness severity and treatment response.</description><identifier>ISSN: 0165-0327</identifier><identifier>EISSN: 1573-2517</identifier><identifier>DOI: 10.1016/0165-0327(91)90003-B</identifier><identifier>PMID: 1829745</identifier><identifier>CODEN: JADID7</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adult ; Agoraphobia - drug therapy ; Agoraphobia - psychology ; Anxiety Disorders - drug therapy ; Anxiety Disorders - psychology ; Arousal - drug effects ; Biological and medical sciences ; Desipramine ; Desipramine - therapeutic use ; Female ; Humans ; Male ; Medical sciences ; Neuropharmacology ; Panic - drug effects ; Panic disorder ; Personality Tests ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Single-Blind Method</subject><ispartof>Journal of affective disorders, 1991-04, Vol.21 (4), p.239-244</ispartof><rights>1991</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-d5869a54d826471b7eaee14cf802de405ad9b658649a64922aaa479028ff63313</citedby><cites>FETCH-LOGICAL-c387t-d5869a54d826471b7eaee14cf802de405ad9b658649a64922aaa479028ff63313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0165-0327(91)90003-B$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19671154$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1829745$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kalus, Oren</creatorcontrib><creatorcontrib>Asnis, Gregory M.</creatorcontrib><creatorcontrib>Rubinson, Eileen</creatorcontrib><creatorcontrib>Kahn, Rene</creatorcontrib><creatorcontrib>Harkavy Friedman, Jill M.</creatorcontrib><creatorcontrib>Iqbal, Naveed</creatorcontrib><creatorcontrib>Grosz, Dan</creatorcontrib><creatorcontrib>van Praag, Herman</creatorcontrib><creatorcontrib>Cahn, Wiepke</creatorcontrib><title>Desipramine treatment in panic disorder</title><title>Journal of affective disorders</title><addtitle>J Affect Disord</addtitle><description>Apart from imipramine (IMI), the efficacy of tricyclic antidepressants in panic disorder (PD) has received surprisingly little investigation. The authors report on a 6 week open trial of desipramine (DMI) preceded by a 10 day placebo lead-in, in 15 patients with PD. By week 6, 80% of the patients were globally rated as much or very much improved on a mean dose of 198 mg. Much of the improvement resulted from a reduction in non-panic attack symptomatology (i.e., psychic, somatic and phobic anxiety). longer duration of illness, male gender and residual psychic anxiety were associated with poorer response in a subgroup of patients. DMI caused minimal intolerable side effects, suggesting possible compliance advantages in comparison to IMI. Beyond supporting the efficacy of DMI in PD, the results of the study point to a significant medication responsive non-panic illness component and caution against over-relying on panic attacks in assessing both illness severity and treatment response.</description><subject>Adult</subject><subject>Agoraphobia - drug therapy</subject><subject>Agoraphobia - psychology</subject><subject>Anxiety Disorders - drug therapy</subject><subject>Anxiety Disorders - psychology</subject><subject>Arousal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Desipramine</subject><subject>Desipramine - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Panic - drug effects</subject><subject>Panic disorder</subject><subject>Personality Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Single-Blind Method</subject><issn>0165-0327</issn><issn>1573-2517</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLAzEUhYMotVb_gcJsfC1Gk0wek41g6xMKbnQd0uQOROZlMhX896ZO0Z2Lw12c717uOQgdE3xFMBHXSTzHBZUXilwqjHGRz3fQlHBZ5JQTuYumv8g-OojxPTFCSTxBE1JSJRmfovM7iL4PpvEtZEMAMzTQDplvs9603mbOxy44CIdorzJ1hKPtnKG3h_vXxVO-fHl8Xtwuc1uUcsgdL4UynLmSCibJSoIBIMxWJaYOGObGqZVIEFMmiVJjDJMK07KqRFGQYobOxrt96D7WEAfd-Gihrk0L3TrqEgtBZUkTyEbQhi7GAJXug29M-NIE600_ehNeb8JrRfRPP3qe1k6299erBtzf0lhI8k-3vonW1FUwrfXxD1NCEsJZ4m5GDlIZnx6CjtZDa8H5AHbQrvP_P_INdHd_Ng</recordid><startdate>19910401</startdate><enddate>19910401</enddate><creator>Kalus, Oren</creator><creator>Asnis, Gregory M.</creator><creator>Rubinson, Eileen</creator><creator>Kahn, Rene</creator><creator>Harkavy Friedman, Jill M.</creator><creator>Iqbal, Naveed</creator><creator>Grosz, Dan</creator><creator>van Praag, Herman</creator><creator>Cahn, Wiepke</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19910401</creationdate><title>Desipramine treatment in panic disorder</title><author>Kalus, Oren ; Asnis, Gregory M. ; Rubinson, Eileen ; Kahn, Rene ; Harkavy Friedman, Jill M. ; Iqbal, Naveed ; Grosz, Dan ; van Praag, Herman ; Cahn, Wiepke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-d5869a54d826471b7eaee14cf802de405ad9b658649a64922aaa479028ff63313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adult</topic><topic>Agoraphobia - drug therapy</topic><topic>Agoraphobia - psychology</topic><topic>Anxiety Disorders - drug therapy</topic><topic>Anxiety Disorders - psychology</topic><topic>Arousal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Desipramine</topic><topic>Desipramine - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Panic - drug effects</topic><topic>Panic disorder</topic><topic>Personality Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Single-Blind Method</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kalus, Oren</creatorcontrib><creatorcontrib>Asnis, Gregory M.</creatorcontrib><creatorcontrib>Rubinson, Eileen</creatorcontrib><creatorcontrib>Kahn, Rene</creatorcontrib><creatorcontrib>Harkavy Friedman, Jill M.</creatorcontrib><creatorcontrib>Iqbal, Naveed</creatorcontrib><creatorcontrib>Grosz, Dan</creatorcontrib><creatorcontrib>van Praag, Herman</creatorcontrib><creatorcontrib>Cahn, Wiepke</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of affective disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kalus, Oren</au><au>Asnis, Gregory M.</au><au>Rubinson, Eileen</au><au>Kahn, Rene</au><au>Harkavy Friedman, Jill M.</au><au>Iqbal, Naveed</au><au>Grosz, Dan</au><au>van Praag, Herman</au><au>Cahn, Wiepke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Desipramine treatment in panic disorder</atitle><jtitle>Journal of affective disorders</jtitle><addtitle>J Affect Disord</addtitle><date>1991-04-01</date><risdate>1991</risdate><volume>21</volume><issue>4</issue><spage>239</spage><epage>244</epage><pages>239-244</pages><issn>0165-0327</issn><eissn>1573-2517</eissn><coden>JADID7</coden><abstract>Apart from imipramine (IMI), the efficacy of tricyclic antidepressants in panic disorder (PD) has received surprisingly little investigation. The authors report on a 6 week open trial of desipramine (DMI) preceded by a 10 day placebo lead-in, in 15 patients with PD. By week 6, 80% of the patients were globally rated as much or very much improved on a mean dose of 198 mg. Much of the improvement resulted from a reduction in non-panic attack symptomatology (i.e., psychic, somatic and phobic anxiety). longer duration of illness, male gender and residual psychic anxiety were associated with poorer response in a subgroup of patients. DMI caused minimal intolerable side effects, suggesting possible compliance advantages in comparison to IMI. Beyond supporting the efficacy of DMI in PD, the results of the study point to a significant medication responsive non-panic illness component and caution against over-relying on panic attacks in assessing both illness severity and treatment response.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>1829745</pmid><doi>10.1016/0165-0327(91)90003-B</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-0327 |
| ispartof | Journal of affective disorders, 1991-04, Vol.21 (4), p.239-244 |
| issn | 0165-0327 1573-2517 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80662782 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Agoraphobia - drug therapy Agoraphobia - psychology Anxiety Disorders - drug therapy Anxiety Disorders - psychology Arousal - drug effects Biological and medical sciences Desipramine Desipramine - therapeutic use Female Humans Male Medical sciences Neuropharmacology Panic - drug effects Panic disorder Personality Tests Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Single-Blind Method |
| title | Desipramine treatment in panic disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T01%3A04%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Desipramine%20treatment%20in%20panic%20disorder&rft.jtitle=Journal%20of%20affective%20disorders&rft.au=Kalus,%20Oren&rft.date=1991-04-01&rft.volume=21&rft.issue=4&rft.spage=239&rft.epage=244&rft.pages=239-244&rft.issn=0165-0327&rft.eissn=1573-2517&rft.coden=JADID7&rft_id=info:doi/10.1016/0165-0327(91)90003-B&rft_dat=%3Cproquest_cross%3E80662782%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80662782&rft_id=info:pmid/1829745&rft_els_id=016503279190003B&rfr_iscdi=true |